Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder.
about
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)Evolution of stimulants to treat ADHD: transdermal methylphenidateAn update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorderDevelopment of a physiologically based model to describe the pharmacokinetics of methylphenidate in juvenile and adult humans and nonhuman primatesAdvances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations.A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects.Brain kinetics of methylphenidate (Ritalin) enantiomers after oral administration.Methylphenidate HCl: therapy for attention deficit hyperactivity disorder.New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder.A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior.Use of methylphenidate in patients with cancer.Differential influences of ethanol on early exposure to racemic methylphenidate compared with dexmethylphenidate in humansEnantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping.Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder.Association of ADHD and the Protogenin gene in the chromosome 15q21.3 reading disabilities linkage region.An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy.Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder.Juvenile methylphenidate exposure and factors that influence incentive processing.Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder.The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension.Methylphenidate transdermal system: clinical applications for attention-deficit/hyperactivity disorder.Should we keep on? Looking into pharmacogenomics of ADHD in adulthood from a different perspective.Model-Based Approach for Optimizing Study Design and Clinical Drug Performances of Extended-Release Formulations of Methylphenidate for the Treatment of ADHD.Monitoring of threo-methylphenidate enantiomers in oral fluid by capillary electrophoresis with head-column field-amplified sample injection.Modulation of motorcortical excitability by methylphenidate in adult voluntary test persons performing a go/nogo task.Subchronic methylphenidate administration has no effect on locomotion, emotional behavior, or water maze learning in prepubertal mice.Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD.Developmental toxicity assessment of d,l-methylphenidate and d-methylphenidate in rats and rabbits.A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.Enantioselective Pharmacokinetics of Bambuterol in Preclinical Species: Does S-bambuterol Influence the Clearance of the R-antipode?Impaired transcallosally mediated motor inhibition in adults with attention-deficit/hyperactivity disorder is modulated by methylphenidate.Effect of Food Intake on the Pharmacokinetics of a Novel Methylphenidate Extended-Release Oral Suspension for Attention Deficit Hyperactivity Disorder.Bioanalysis of chiral compounds during drug development using a tiered approach.Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers.
P2860
Q22061981-78BB3E26-60A3-4C1C-8C71-6797FDCFEAD0Q22252903-B94A10CC-8951-4FEE-9917-7BF7EA4399AAQ28246274-FBBCDA94-F972-460B-90A9-D3F10F163B44Q28393582-687A55D2-5360-4797-9DBA-5DCD075754B1Q34273853-CAD0D886-3599-4DA7-94C7-9C12C6119AFCQ34293071-4FEF3AF0-8176-4D35-99E1-249C0F18441BQ34331397-2784B26B-C943-4AB1-9013-C38E8F6CA117Q34424163-4448C356-3D78-4C2E-8D6D-787A4DD6E4DEQ34468658-D520D990-271A-48FD-9AD3-DFFA8C25B119Q35709161-33FC9C12-B024-4FAA-9C22-0636FB8943A5Q36383595-C1D97FC4-3930-45F9-9611-9B433BA062BBQ36497637-A7AFABAD-70E9-44EF-A479-2BAC58A2D057Q36596952-6FF18D25-A079-49D1-8161-1603381E1902Q36787283-316E2251-C22D-4EFB-BFDA-39EE1D95ACB0Q36803173-5761CF2B-F77C-4533-BEE7-99DA9CF71871Q37038995-A5A43E93-2BD7-4C9B-94FD-ABB9B26820CEQ37166164-DE7FB753-6315-4585-AE68-6FCFE74715EAQ37608818-070A1608-BAD9-4C4A-8D7A-A605FFA4D220Q37643681-B025837A-565F-4D58-9F21-D45D404E8885Q37791311-981376FB-8CA8-4DE2-8F3F-3D2E636FBE58Q37960505-2C9B76FE-46DE-4657-9A2B-F5E8BA0F57A9Q38243174-C7D4508F-9A62-4E64-BA95-B15F1A7AD264Q38859853-6F7782D4-2721-4B46-B09D-5FD3AC6A11ABQ42244335-9577AC34-A41D-49E9-AE4B-804C7FFBEC5DQ43220754-D41EC350-7338-4483-8A2C-CF7796781BA5Q44124123-41AF9314-5921-410A-B18D-A1DFD7801D6FQ46121475-A56829EC-298F-4F9E-A58A-2F8077D40D29Q46314234-094B4786-BDA5-4510-A6A6-EBCF466D1D82Q46502033-B639DA9F-06BA-4C1E-8EDD-69448402A699Q46606172-A31C16EB-86E9-4747-A3F9-D1E4E14D5047Q46807702-4B0CA53D-745C-470E-9AFC-9EAE8321541CQ50578470-ECC2A6AF-05A9-4C91-9752-53D2E77E464AQ51748942-B92E55AD-A00E-47B2-B256-E7680AAEFC71Q54574209-A944960A-69F0-4B7F-82D3-B58DCC33D70D
P2860
Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder.
description
1992 nî lūn-bûn
@nan
1992 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Enantioselective pharmacokinet ...... eficit hyperactivity disorder.
@ast
Enantioselective pharmacokinet ...... eficit hyperactivity disorder.
@en
type
label
Enantioselective pharmacokinet ...... eficit hyperactivity disorder.
@ast
Enantioselective pharmacokinet ...... eficit hyperactivity disorder.
@en
prefLabel
Enantioselective pharmacokinet ...... eficit hyperactivity disorder.
@ast
Enantioselective pharmacokinet ...... eficit hyperactivity disorder.
@en
P2093
P356
P1476
Enantioselective pharmacokinet ...... eficit hyperactivity disorder.
@en
P2093
P304
P356
10.1038/CLPT.1992.185
P407
P577
1992-11-01T00:00:00Z